A strong performance by recently-launched drugs in this year’s second quarter allowed Roche on 25 July to beat market forecasts and to raise its 2019 full-year outlook for the second time this year, boosted by management’s rising confidence that it can ride out a wave of biosimilars entering the US market in the second half and continue growing earnings into 2020.
Roche said second-quarter group sales grew 9% at constant exchange rates, with the pharma division revenue up 11%, driven mainly...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
